People: CEL-SCI Corp (CVM)
CVM on American Stock Exchange
0.25USD
24 May 2013
0.25USD
24 May 2013
Price Change (% chg)
$-0.00 (-0.40%)
$-0.00 (-0.40%)
Prev Close
$0.25
$0.25
Open
$0.25
$0.25
Day's High
$0.25
$0.25
Day's Low
$0.25
$0.25
Volume
488,933
488,933
Avg. Vol
1,074,098
1,074,098
52-wk High
$0.47
$0.47
52-wk Low
$0.20
$0.20
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Maximilian de Clara |
82 | 1983 | President, Director |
Geert Kersten |
53 | 1995 | Chief Executive Officer, Treasurer, Director |
Patricia Prichep |
61 | 2000 | Senior Vice President - Operations, Corporate Secretary |
John Cipriano |
70 | 2009 | Senior Vice President - Regulatory Affairs |
Daniel Zimmerman |
71 | 2009 | Senior Vice President - Research, Cellular Immunology |
Eyal Talor |
56 | 2009 | Chief Scientific Officer |
Alexander Esterhazy |
70 | 1999 | Independent Director |
C. Richard Kinsolving |
76 | 2001 | Independent Director |
Peter Young |
67 | 2002 | Independent Director |
Gavin de Windt |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Maximilian de Clara |
Mr. Maximilian de Clara is President, Director of CEL-SCI Corporation. He has been a Director of CEL-SCI since its inception in March l983, and has been President of CEL-SCI since July 1983. Prior to his affiliation with CEL-SCI, and since at least l978, Mr. de Clara was involved in the management of his personal investments and personally funding research in the fields of biotechnology and biomedicine. Mr. de Clara attended the medical school of the University of Munich from 1949 to l955, but left before he received a medical degree. During the summers of l954 and l955, he worked as a research assistant at the University of Istanbul in the field of cancer research. For his efforts and dedication to research and development in the fight against cancer and AIDS, Mr. de Clara was awarded the "Pour le Merit" honorary medal of the Austrian Military Order "Merito Navale" as well as the honor cross of the Austrian Albert Schweitzer Society. |
Geert Kersten |
Mr. Geert R. Kersten, Esq., is Chief Executive Officer, Treasurer, Director of CEL-SCI Corporation since February 1995. He has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI from the early days of its inception since 1987. He has been involved in the pioneering field of cancer immunotherapy for almost two decades and has steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with the experience in the fields of finance and law and has a unique vision of how the company's Multikine product will change the way cancer is treated. Prior to CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from Millfield School in England, and completed his studies in the US. Mr. Kersten completed his Undergraduate Degree in Accounting, received an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC. |
Patricia Prichep |
Ms. Patricia B. Prichep is Senior Vice President - Operations, Corporate Secretary of CEL-SCI Corporation. She joined CEL-SCI in 1992 and has been CEL-SCI's Senior Vice President of Operations since March 1994. Between December 1992 and March 1994, Ms. Prichep was CEL-SCI's Director of Operations. Ms. Prichep became CEL-SCI's Corporate Secretary in May 2000. She is responsible for all day-to-day operations of the Company, including human resources and is the liaison with CEL-SCI's independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD's Management, Systems and Support Department. She was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for the company and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut. |
John Cipriano |
Mr. John Cipriano is Senior Vice President - Regulatory Affairs of CEL-SCI Corporation. He has been CEL-SCI's Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009. Mr. Cipriano brings to CEL-SCI 30 years of experience in both biotech and pharmaceutical companies. In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana. |
Daniel Zimmerman |
Dr. Daniel H. Zimmerman, Ph.D., is Senior Vice President - Research, Cellular Immunology of CEL-SCI Corporation. He was CEL-SCI's Senior Vice President of Cellular Immunology between 1996 and December 2008 and again since November 2009. He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995. From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman holds over a dozen US patents as well as many foreign equivalent patents. He is the author of over 40 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from NIH and DOD. From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a guest worker. Dr Zimmerman received a Ph.D. in Biochemistry in 1969, a Masters in Zoology in 1966 from the University of Florida and a B.S. in Biology from Emory and Henry College in 1963. |
Eyal Talor |
Dr. Eyal Talor, Ph.D., is Chief Scientific Officer of CEL-SCI Corporation. He joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion he was the Senior Vice president of Research and Manufacturing, since March of 1994. He is a clinical immunologist with over 19 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III, in the biopharmaceutical industry. His experience includes; biopharmaceutical R&D and Biologics product development, GMP manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of clinical trials (Phase I - III) and GCP requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has the experience in the preparation of documentation for IND and other regulatory submissions. Before coming to CEL-SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full time faculty member at The Johns Hopkins University, Medical Intuitions; School of Public Health. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The John Hopkins University, Baltimore, Maryland, USA. He holds an Adjunct Associate teaching position at the Johns Hopkins University Medical Institutions. |
Alexander Esterhazy |
Mr. Alexander G. Esterhazy is Independent Director of CEL-SCI Corporation. He has been a Director of CEL-SCI since December 1999 and has been an independent financial advisor since November 1997. Between July 1991 and October 1997, Mr. Esterhazy was a senior partner of Corpofina S.A. Geneva, a firm engaged in mergers, acquisitions and portfolio management. Between January 1988 and July 1991, Mr. Esterhazy was a managing director of DG Bank in Switzerland. During this period Mr. Esterhazy was in charge of the Geneva, Switzerland branch of the DG Bank, founded and served as vice president of DG Finance (Paris) and was the President and Chief Executive officer of DG-Bourse, a securities brokerage firm. |
C. Richard Kinsolving |
Dr. C. Richard Kinsolving, Ph.D., is Independent Director of CEL-SCI Corporation. He has been a Director of CEL-SCI since April 2001. Since February 1999, Dr. Kinsolving has been the Chief Executive Officer of BioPharmacon, a pharmaceutical development company. Between December 1992 and February 1999, Dr. Kinsolving was the President of Immuno-Rx, Inc., a company engaged in immuno-pharmaceutical development. Between December 1991 and September 1995, Dr. Kinsolving was President of Bestechnology, Inc. a nonmedical research and development company producing bacterial preparations for industrial use. Dr. Kinsolving received his Ph.D. in Pharmacology from Emory University (1970), his Masters degree in Physiology/Chemistry from Vanderbilt University (1962), and his Bachelor's degree in Chemistry from Tennessee Tech. University (1957). |
Peter Young |
Dr. Peter R. Young, Ph.D., is Independent Director of CEL-SCI Corporation. He has been a Director of CEL-SCI since August 2002. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career. Over the last 20 years he has primarily held positions of Chief Executive Officer or Chief Financial Officer and has the experience with acquisitions and equity financings. Since November 2001, Dr. Young has been the President of Agnus Dei, LLC, which acts as a partner in an organization managing immune system clinics which treat patients with diseases such as cancer, multiple sclerosis and hepatitis. Since January 2003, Dr. Young has been the President and Chief Executive Officer of SRL Technology, Inc., a company involved in the development of pharmaceutical (drug) delivery systems. Between 1998 and 2001, Dr. Young was the Chief Financial Officer of Adams Laboratories, Inc. Dr. Young received his Ph.D. in Organic Chemistry from the University of Bristol, England (1969), and his Bachelor's degree in Honors Chemistry, Mathematics and Economics also from the University of Bristol, England (1966). |
Gavin de Windt |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Maximilian de Clara |
666,454 |
Geert Kersten |
881,811 |
Patricia Prichep |
385,847 |
John Cipriano |
260,782 |
Daniel Zimmerman |
332,746 |
Eyal Talor |
415,612 |
Alexander Esterhazy |
-- |
C. Richard Kinsolving |
-- |
Peter Young |
-- |
Gavin de Windt |
-- |
As Of 29 Sep 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Maximilian de Clara |
1,688,665 | 1,684,049 |
Geert Kersten |
3,758,750 | 917,210 |
Patricia Prichep |
1,254,500 | 345,540 |
John Cipriano |
210,000 | 6,800 |
Daniel Zimmerman |
889,000 | 322,800 |
Eyal Talor |
972,666 | 446,693 |
Alexander Esterhazy |
0 | 0 |
C. Richard Kinsolving |
0 | 0 |
Peter Young |
0 | 0 |
Gavin de Windt |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
KERSTEN GEERT R |
118,700 | $0.27 |
ZIMMERMAN DANIEL H |
14,413 | $0.23 |
TALOR EYAL |
10,434 | $0.23 |
PRICHEP PATRICIA B |
15,726 | $0.23 |
KERSTEN GEERT R |
16,630 | $0.23 |
PRICHEP PATRICIA B |
25,000 | $0.22 |
YOUNG PETER R |
25,000 | $0.23 |
KERSTEN GEERT R |
200,000 | $0.22 |
KERSTEN GEERT R |
148,125 | $0.21 |
KERSTEN GEERT R |
13,888 | $0.27 |
PRICHEP PATRICIA B |
12,338 | $0.27 |
TALOR EYAL |
8,888 | $0.27 |
ZIMMERMAN DANIEL H |
11,713 | $0.27 |
KERSTEN GEERT R |
10,714 | $0.35 |
ZIMMERMAN DANIEL H |
8,788 | $0.35 |
PRICHEP PATRICIA B |
9,262 | $0.35 |
TALOR EYAL |
6,857 | $0.35 |
KERSTEN GEERT R |
9,868 | $0.38 |
PRICHEP PATRICIA B |
8,531 | $0.38 |
ZIMMERMAN DANIEL H |
8,094 | $0.38 |
TALOR EYAL |
6,315 | $0.38 |
PRICHEP PATRICIA B |
6,945 | $0.48 |
TALOR EYAL |
5,000 | $0.48 |
KERSTEN GEERT R |
7,812 | $0.48 |
ZIMMERMAN DANIEL H |
6,589 | $0.48 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
